Remedent, Inc.
REMI · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.00 | -0.23 | 0.29 |
| FCF Yield | -9.99% | -1.56% | -4.97% | 0.05% |
| EV / EBITDA | -5.94 | -2.28 | -21.00 | -36.64 |
| Quality | ||||
| ROIC | -5.34% | -10.47% | 8.39% | -0.74% |
| Gross Margin | 61.17% | 58.53% | 74.38% | 56.18% |
| Cash Conversion Ratio | 0.48 | 0.16 | -1.16 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.18% | -5.69% | 9.76% | -13.72% |
| Free Cash Flow Growth | -145.91% | 68.59% | -9,916.85% | -98.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.07 | 1.13 | 0.71 |
| Interest Coverage | 0.00 | -68.50 | 42.87 | -8.58 |
| Efficiency | ||||
| Inventory Turnover | 4.17 | 3.86 | 3.82 | 4.41 |
| Cash Conversion Cycle | -1,823.05 | -1,027.13 | -1,913.13 | -1,592.38 |